Author: Patrick Nelson

In this session AEM Executive Chairman, Richard Seville discusses why High-Purity Alumina (HPA) is a critical mineral in high demand.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

In this session AEM Executive Chairman, Richard Seville discusses why High-Purity Alumina (HPA) is a critical mineral in high demand.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

CEO Steve Wildisen discusses how Xsights combines Internet of Things (IoT) devices and machine learning technology to monitor the health and wellbeing of farmed pigs, with their patented technology – the Xiot Health Tag – on track to reduce pig morality by 45%.

Xsights combines Internet of Things (IoT) devices and machine learning technology to monitor the health and wellbeing of farmed pigs, offering the potential to save billions of dollars for operators and tens of millions of currently wasted animal lives.

John Forwood, CIO of Lowell Resources Fund, discusses his ‘blue-sky’ thesis for Plutonic and compares it to previous portfolio winners.

Hedley Widdup, CEO of leading resources fund manager Lion Selection Group (ASX:LSX), discusses why he believes that Plutonic represents a “once in a cycle” opportunity, elaborating on their progress and pathway to IPO.

Plutonic founder Dr Kris Butera discusses his flagship Champion project, expanding on why he believes there is potential for a resource deposit that is “unlike anything he has ever seen.” Kris talks through his team’s four year exploration journey and provides examples of the mineralisation present within the high priority prosepect areas.

Alta CEO Nick Langton sits down with Mark Bouris and STAKE to discuss the company’s journey from inception to going public on the NYSE and reaching a market cap of $42.3 million.

Xsights combines Internet of Things (IoT) devices and machine learning technology to monitor the health and wellbeing of farmed pigs, offering the potential to save billions of dollars for operators and tens of millions of currently wasted animal lives.

In this session Far East Gold’s CEO and Director Shane Menere discussed the standout assays from our Woyla drilling campaigns that form the base of our upcoming maiden JORC resource publication.

In this session Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke discussed the an update on Prescient’s strategy and upcoming milestones, with a focus on PTX-100.

In this session AEM Executive Chairman, Richard Seville discusses why High-Purity Alumina (HPA) is a critical mineral in high demand.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

In this session AEM Executive Chairman, Richard Seville discusses why High-Purity Alumina (HPA) is a critical mineral in high demand.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

Stuart Roberts, co-founder and senior analyst at Pitt Street Research, outlined the recent Pitt Street Research report on Prescient Therapeutics.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

Disrupting a $300bn industry which has not seen innovation in decades

Large-scale, development-ready, copper project with the potential to become a top-10 US producer.

One of the most advanced cancer therapies on the ASX, Prescient Therapeutics’ (ASX: PTX) PTX-100 is a first-in-class technology which has seen the cancer halt or reduce in 100% of assessable CTCL patients and zero drug related serious adverse events....

Advanced Energy Minerals (ASX: AEM) is the only ASX-listed commercial-scale High Purity Alumina (HPA) producer and one of the only companies globally able to produce ultra-low alpha HPA at commercial scale - a critical material used in advanced AI chips. China controls...

Having moved to Silicon Valley, Australian big data / AI company Zetaris is at the centre of solving one of the biggest bottlenecks within the most significant shift in our lifetime, targeting a billion dollar plus exit in the next 1-2...

If you’re an Australian investor asking, “Where can I still get a decent cash yield?” – you’re not alone.

Australian big data company Xsights has managed what most tech companies dream of: the potential to sign contracts worth $100s million ARR with companies worth $100s billion, driven mostly by inbound demand.

One in five people will get cancer in their lifetime – almost everyone has been touched by the disease in one way or another.

A potential once-in-a-generation opportunity has opened up for the companies that can deliver the critical metals projects the world needs for the green energy transition.

The global antimony market has undergone a dramatic transformation.

Australian tech company Xsights is set to disrupt the ~$300 billion global pork production market.

Since Trump has taken over, we have seen tariffs, trade wars and a massive spike in market volatility.

People have historically been skeptical of Bitcoin, but recently even the largest financial institutions like BlackRock, JP Morgan and Goldman Sachs have moved into the asset class due to its growth prospects and diversification benefits.

As copper moves up in price and into the headlines, Australian developer Copper Bay is preparing for a 2025 IPO on the ASX.

In this session AEM Executive Chairman, Richard Seville discusses why High-Purity Alumina (HPA) is a critical mineral in high demand.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

In this session AEM Executive Chairman, Richard Seville discusses why High-Purity Alumina (HPA) is a critical mineral in high demand.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

Stuart Roberts, co-founder and senior analyst at Pitt Street Research, outlined the recent Pitt Street Research report on Prescient Therapeutics.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

Please join Connec Chairman Kim Manley for an investor briefing.

Please join Connec Chairman Kim Manley for an investor briefing.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

Stuart Roberts, co-founder and senior analyst at Pitt Street Research, outlined the recent Pitt Street Research report on Prescient Therapeutics.

Please join Prescient Therapeutics CEO James McDonnell for an investor briefing.

Please join Xsights Co-Founder and CEO Steve Wildisen for an investor briefing.

Please join Connec Chairman Kim Manley for an investor briefing.

Please join Felix Gold Executive Director Joe Webb for an investor briefing.

Please join Wellnex Life Managing Director, Zack Bozinvoski for an investor briefing.

Please join TRIBE CEO Anthony Svirskis for an investor briefing.

Join Far East Gold Non-Executive Chairman Justin Werner for a live and online Q&A session.

Join MDF’s Managing Director Joseph Webb for an investor briefing.

Please join Propell CEO Michael Davidson for an investor briefing.

In this session AEM Executive Chairman, Richard Seville discusses why High-Purity Alumina (HPA) is a critical mineral in high demand.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

In this session AEM Executive Chairman, Richard Seville discusses why High-Purity Alumina (HPA) is a critical mineral in high demand.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.